Literature DB >> 2039825

Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis.

A Foti1, H G Ahuja, S L Allen, P Koduru, M W Schuster, P Schulman, M Bar-Eli, M J Cline.   

Abstract

A patient with typical Philadelphia chromosome (Ph1)-positive chronic myelocytic leukemia (CML) was studied during sequential phases of disease: (1) initial chronic phase; (2) myeloid blast crisis; (3) second chronic phase; and (4) accelerated disease. A point mutation in the coding sequence of the p53 gene first appeared concomitantly with the blast crisis and then disappeared with the re-establishment of a second chronic phase. The chromosomal concomitant of the molecular alteration was a deletion of 17p. These observations suggest that abnormalities of the p53 anti-oncogene are temporally related to the clinical progression of some cases of CML and are probably responsible for the development of blast crisis in these cases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039825

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment.

Authors:  R Radinsky
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

2.  P53 tumor suppressor gene in chronic myelogenous leukemia: a sequential study.

Authors:  A Rovira; A Urbano-Ispizua; F Cervantes; M Rozman; J L Vives-Corrons; E Montserrat; C Rozman
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

3.  p53 gene rearrangements in chronic myelocytic leukemia.

Authors:  A Hernández; P Hernández; L Corral; A Muñiz; C Alaez; E Espinosa; O Fernández; G Martinez
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

4.  Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.

Authors:  K Mitani; S Ogawa; T Tanaka; H Miyoshi; M Kurokawa; H Mano; Y Yazaki; M Ohki; H Hirai
Journal:  EMBO J       Date:  1994-02-01       Impact factor: 11.598

5.  Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.

Authors:  T Skorski; M Nieborowska-Skorska; K Campbell; R V Iozzo; G Zon; Z Darzynkiewicz; B Calabretta
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

6.  Detection of p53 gene mutations in aspiration biopsy specimens from suspected breast cancers by polymerase chain reaction-single strand conformation polymorphism analysis.

Authors:  T Sato; A Okazaki; M Okazaki; S Takahashi; K Hirata
Journal:  Jpn J Cancer Res       Date:  1995-02

7.  p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.

Authors:  T Nakamura; I Yana; T Kobayashi; E Shin; K Karakawa; S Fujita; A Miya; T Mori; I Nishisho; S Takai
Journal:  Jpn J Cancer Res       Date:  1992-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.